Topical loperamide
This article was originally published in The Tan Sheet
Executive Summary
SmithKline Beecham and Adolor sign licensing agreement for worldwide (excluding Korea) prescription and OTC development and commercial rights to the topical dermal ingredient ADL 2-1294 (loperamide) used for the treatment of inflammatory pain and itching. If multiple indications for the ingredient are found, Adolor will receive up to $48 mil. from development payments as well as a licensing fee and equity investment from SmithKline. Loperamide is sold as an OTC oral antidiarrhea. The reference product is McNeil Consumer Healthcare's Imodium
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning